• Publications
  • Influence
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).
Clinical risk classification is inaccurate in predicting relapse in adult patients with acute lymphoblastic leukemia, sometimes resulting in patients receiving inappropriate chemotherapy or stem cellExpand
  • 321
  • 13
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients.
The clinical outcome, response to treatment, and occurrence of acute complications were retrospectively investigated in 308 primary autoimmune hemolytic anemia (AIHA) cases and correlated withExpand
  • 136
  • 13
Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.
Myelodysplastic syndromes (MDSs) arise from a defective hematopoietic stem/progenitor cell. Consequently, there is an urgent need to develop targeted therapies capable of eliminating theExpand
  • 135
  • 11
Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis.
OBJECTIVE Circulating endothelial cells (CECs) have been described in different conditions involving vascular injury. Vascular abnormalities play a key role in the pathogenesis of systemic sclerosisExpand
  • 165
  • 10
Angiogenesis in myelodysplastic syndromes
It is now well established that solid tumour growth depends on angiogenesis. However, less is known about the generation of new vessels in haematological malignancies and, in particular, inExpand
  • 279
  • 9
Hepcidin Levels and Their Determinants in Different Types of Myelodysplastic Syndromes
Iron overload may represent an additional clinical problem in patients with Myelodysplastic Syndromes (MDS), with recent data suggesting prognostic implications. Beyond red blood cells transfusions,Expand
  • 70
  • 9
Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome
This study evaluated the impact of a new epoetin alfa dosing regimen on quality of life (QOL), transfusion requirements, and hemoglobin (Hb) levels in 133 patients with low-risk myelodysplasticExpand
  • 98
  • 8
RAS Mutations Contribute to Evolution of Chronic Myelomonocytic Leukemia to the Proliferative Variant
Purpose: The biological and clinical heterogeneity of chronic myelomonocytic leukemia features renders its classification difficult. Moreover, because of the limited knowledge of the mechanismsExpand
  • 88
  • 7
Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia.
The aim of this multicenter GIMEMA study was to correlate autoimmune complications (AIC) in B-cell chronic lymphocytic leukemia (B-CLL) with stage and therapy. Autoimmune hemolytic anemia (129/194Expand
  • 83
  • 7
Autoimmune cytopenias in chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is frequently complicated by secondary autoimmune cytopenias (AIC) represented by autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), pure red cellExpand
  • 47
  • 7